To NASDAQ OMX Copenhagen A/S
Announcement No. 22-12 / Copenhagen, November 26, 2012
Today Topotarget A/S held an Extraordinary General Meeting at Symbion, Fruebjergvej 3, DK-2100 Copenhagen Ø. All proposals made by the Board of Directors were adopted as proposed.
At the meeting, the Board of Directors’ proposals were adopted as proposed. Hence, it was resolved by the general meeting to (i) amend the Articles of Association by including a new Article 7(a) authorizing the Board of Directors to take up loans against issuance of convertible bonds and to increase the share capital by a nominal value of up to DKK 13,260,902 by conversion of convertible bonds, and (ii) approve revised general guidelines for incentive remuneration of the Company's Board of Directors and Management. For the full text of the proposals made by the Board of Directors please see the convening notice (Topotarget A/S’ company announcement no. 19-12 of November 2, 2012). The revised guidelines will be made available at Topotarget A/S’ website.
Topotarget A/S
For further information, please contact:
Anders Vadsholt, CEO: Direct: +45 39178345; Cell: +45 28989055
Background information
About Topotarget
Topotarget (NASDAQ OMX: TOPO) is an international biopharmaceutical company headquartered in Copenhagen, Denmark, dedicated to clinical development and registration of oncology products. In collaboration with Spectrum Pharmaceuticals, Inc., Topotarget focuses on the development of its lead drug candidate, belinostat, which has shown positive results in the treatment of hematological malignancies and solid tumors, obtained by both mono- and combination therapy. For more information, please refer to www.topotarget.com.
Topotarget Safe Harbor Statement
This announcement may contain forward-looking statements, including statements about Topotarget A/S’ expectations to the progression of Topotarget A/S’ clinical pipeline and with respect to cash burn guidance. Such statements are subject to risks and uncertainties of which many are outside the control of Topotarget A/S, and which could cause actual results to differ materially from those described. Topotarget A/S disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by Danish law.
